The biomanufacturing technology provider received more backing from Alphabet subsidiary Verily in its series B round and has now raised over $100m to date.

US-based biomanufacturing technology developer Culture Biosciences has received $80m in a series B round featuring Verily Life Sciences, the life science innovation arm of internet and technology group Alphabet.

Venture capital firm Northpond Ventures led the round and was joined by Synthesis Capital, The Production Board, Cultivian Sandbox Ventures, the MIT Media Lab-affiliated E14 Fund, Craft Ventures and Section 32.

Founded in 2016, Culture has built a a cloud-based platform that allows researchers to carry out bioreactor experiments – a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn